S E S Lange1, J Liu2, D R Adkins3, M A Powell4, B A Van Tine3, D G Mutch4. 1. Division of Gynecologic Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States. Electronic address: langes@wudosis.wustl.edu. 2. Division of Public Health Sciences, Washington University in St. Louis, St. Louis, MO 63110, United States. 3. Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, United States. 4. Division of Gynecologic Oncology, Washington University in St. Louis, St. Louis, MO 63110, United States; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, United States.
Abstract
OBJECTIVE: A retrospective chart review was performed to determine patient outcomes before and after partnership by gynecologic oncologists (GYN/ONC) with a sarcoma center (SC) for patients with recurrent unresectable/metastatic (RM) uterine leiomyosarcoma (uLMS). METHODS: 58 RM patients, identified from medical records of uLMS patients cared for by either GYN/ONC service and/or the SC between 1/1/2000-4/1/2014, were audited for patient and tumor characteristics, outcomes, and clinical trials enrollments. RESULTS: Of the 58 patients, 26 patients (48%) were treated by GYN/ONC alone and 32 were treated by a combination of GYN/ONC and SC (52%). Age, race, tumor size, grade, presence of lymphovascular invasion, cervical involvement, and FIGO stage at diagnosis were not statistically different between the two groups. There was a significant difference between the number of clinical trial enrollments (0.07 vs 0.84 trials/patient, p<0.001) and the number of chemotherapy regimens prescribed (2.67 vs 4.29/patient, p=0.03) by GYN/ONC vs SC; the latter was driven by the number of clinical trial enrollments by the SC. Sixty-nine percent of patients referred to the SC were enrolled in at least one clinical trial, while just 8% of patients in the GYN/ONC group were enrolled in at least one clinical trial, a difference that is significant (p<0.0001). CONCLUSIONS: Referral of RM uLMS patients by GYN/ONC to a dedicated clinical trials-based SC resulted in an increase in the number of chemotherapy regimens prescribed and clinical trial enrollments. Partnership between GYN/ONC and a dedicated SC with access to clinical trials should be encouraged for all RM uLMS patients.
OBJECTIVE: A retrospective chart review was performed to determine patient outcomes before and after partnership by gynecologic oncologists (GYN/ONC) with a sarcoma center (SC) for patients with recurrent unresectable/metastatic (RM) uterine leiomyosarcoma (uLMS). METHODS: 58 RM patients, identified from medical records of uLMS patients cared for by either GYN/ONC service and/or the SC between 1/1/2000-4/1/2014, were audited for patient and tumor characteristics, outcomes, and clinical trials enrollments. RESULTS: Of the 58 patients, 26 patients (48%) were treated by GYN/ONC alone and 32 were treated by a combination of GYN/ONC and SC (52%). Age, race, tumor size, grade, presence of lymphovascular invasion, cervical involvement, and FIGO stage at diagnosis were not statistically different between the two groups. There was a significant difference between the number of clinical trial enrollments (0.07 vs 0.84 trials/patient, p<0.001) and the number of chemotherapy regimens prescribed (2.67 vs 4.29/patient, p=0.03) by GYN/ONC vs SC; the latter was driven by the number of clinical trial enrollments by the SC. Sixty-nine percent of patients referred to the SC were enrolled in at least one clinical trial, while just 8% of patients in the GYN/ONC group were enrolled in at least one clinical trial, a difference that is significant (p<0.0001). CONCLUSIONS: Referral of RM uLMS patients by GYN/ONC to a dedicated clinical trials-based SC resulted in an increase in the number of chemotherapy regimens prescribed and clinical trial enrollments. Partnership between GYN/ONC and a dedicated SC with access to clinical trials should be encouraged for all RM uLMS patients.
Authors: Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout Journal: Gynecol Oncol Date: 2003-06 Impact factor: 5.482
Authors: Martee L Hensley; Nicole Ishill; Robert Soslow; Joseph Larkin; Nadeem Abu-Rustum; Paul Sabbatini; Jason Konner; William Tew; David Spriggs; Carol A Aghajanian Journal: Gynecol Oncol Date: 2009-01-09 Impact factor: 5.482
Authors: Terrance L Albrecht; Susan S Eggly; Marci E J Gleason; Felicity W K Harper; Tanina S Foster; Amy M Peterson; Heather Orom; Louis A Penner; John C Ruckdeschel Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544
Authors: Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482
Authors: Roman Groisberg; David S Hong; Vijaykumar Holla; Filip Janku; Sarina Piha-Paul; Vinod Ravi; Robert Benjamin; Shreyas Kumar Patel; Neeta Somaiah; Anthony Conley; Siraj M Ali; Alexa B Schrock; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Shiraj Sen; Cynthia Herzog; Funda Meric-Bernstam; Vivek Subbiah Journal: Oncotarget Date: 2017-06-13
Authors: Rachel G Greenberg; Amy Corneli; John Bradley; John Farley; Hasan S Jafri; Li Lin; Sumathi Nambiar; Gary J Noel; Chris Wheeler; Rosemary Tiernan; P Brian Smith; Jamie Roberts; Daniel K Benjamin Journal: Contemp Clin Trials Commun Date: 2017-11-26